Glioblastoma is the most common malignant brain tumor in adults. The primary treatment consists of maximal tumor removal followed by radiotherapy (RT) with concomitant and adjuvant temozolomide. Tumor recurrence after chemoradiotherapy has previously been shown to be predominantly within or at the margin of the irradiated volume, but distant failure are not rare, especially in patients with MGMT methylation.Traditionally, RT has been planned based on on planning CT with co-registered postoperative MRI, with the addition of a clinical target volume margin of 2-3 cm to account for infiltrative odema. To better characterize the disease, more specific physiological and/or metabolical markers of tumor cells, vascularization and hypoxia measured on multiparametric MRI as perfusion, diffusion and spectroscopy alongside with PET tracer like Fluoroéthyl-L-tyrosine (\[18F\]-FET) are now available and suggest that aggressive areas, like uptake of PET tracer and vascularity are present outside areas of contrast enhancement usually irradiated. These informations could be incorporated to optimize the treatment of radiotherapy.
Study Type
OBSERVATIONAL
Enrollment
30
CHRU de Brest
Brest, France
RECRUITINGTarget volumes contoured on standard MRI and planning CT, FET-PET and multiparametric MRI images
Increase in at least 10% of irradiation target volumes compared to the result of the MRI+scanner reference technique.
Time frame: 12 months
Treatment failure pattern in respect to the target volume based on standard MRI, multiparametric MRI and FET-PET.
Irradiation target volumes associated with standard MRI
Time frame: 12 months
Sites of failures with composite and standard MRI based RT planning
Irradiation target volumes associated with standard MRI based RT planning
Time frame: 12 months
Progression-free Survival
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.